Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study
{{output}}
Background: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC). We previously reported the efficacy of biweekly carboplatin p... ...
